New Treatment Guidelines for Rheumatoid Arthritis
August 26, 2008 by MedHeadlines
Filed under Rheumatoid Arthritis
The success of new anti-arthritis drugs and combinations of proven medicines have led the American College of Rheumatology to issue updated guidelines for the treatment of rheumatoid arthritis (RA), the first revisions to treatment recommended since 2002. Read more
FDA Investigates JIA, TNF Blockers, and Cancer in Children
June 4, 2008 by MedHeadlines
Filed under Adolescents, Cancer, Children's Health, Crohn's Disease, Drugs, FDA, Prevention, Rheumatoid Arthritis
The US Food and Drug Administration (FDA) has just announced an investigation into the link between certain drugs known as tumor necrosis factor (TNF) blockers and the development of cancer in children and young adults taking these medications. TNF blockers are routinely prescribed to children aged 18 and younger to treat conditions such as Juvenile Idiopathic Arthritis (JIA), formerly known as Juvenile Rheumatoid Arthritis (JRA), Crohn’s disease, and other diseases of the immune system. Read more
Humira Approved for Treatment of Juvenile Rheumatoid Arthritis
February 26, 2008 by MedHeadlines
Filed under Children's Health, Drugs, FDA, Rheumatoid Arthritis
Humira, a drug commonly given to adult patients to treat rheumatoid arthritis, has now been approved to treat similar ailments in juvenile patients. Abbott recently announced that they received approval from the U.S. Food and Drug Administration to market Humira (adalimumab) as treatment to reduce the symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older. Read more
Loading ...
